Samsung Bioepis bolstered by EMA recommendation of Enbrel biosimilar

By Dan Stanton contact

- Last updated on GMT

The biosimilar will face the European Commission next year - photo Istock/artJazz
The biosimilar will face the European Commission next year - photo Istock/artJazz

Related tags: Samsung bioepis, Etanercept

The EMA has given the thumbs up to Benepali, a biosimilar of Amgen’s Enbrel developed by Samsung Bioepis, a JV between Biogen and Samsung Biologics.

Samsung Bioepis - a joint venture between Samsung Biologics and Biogen– submitted Benepali (etanercept) for review by the European Medicines Agency (EMA) in January​.

Last week the firms received a positive opinion from the Agency’s Committee for Medicinal Products for Human Use (CHMP), meaning the candidate has been recommended for approval by the European Commission, whose decision is expected next year.

“The positive opinion for Benepali puts us on track to bring the first biosimilar of Enbrel to market in Europe,”​ Biogen spokesperson Shannon Altimari told Biopharma-Reporter.com. “The CHMP opinion marks the JV’s first regulatory milestone in Europe.”

The JV was formed in 2012 between Korea’s Samsung and Switzerland Biogen and has a number of biosimilars in its pipeline on top of Benepali (formerly known as SB4).

“Samsung Bioepis has filed for SB2 (infliximab – a version of J&J’s Remicade) approval with the EC, the CHMP opinion for that compound is expected 1H2016,”​ Altimari said.

“Recently, Phase III data for SB5 (adalimumab) was presented at the ACR meeting in San Francisco. The data confirmed a high level of biosimilarity between SB5 and the reference product, [AbbVie’s] Humira.”

Biogen owns the commercialisation rights for Benepali in Europe, Switzerland, and Japan, while Merck & Co. (known as MSD outside North America) will commercialise the biosimilar in all other markets, excluding the US, and is expected to launch the product in Korea​ before the end of the year.

In the US, Amgen has secured secondary patents intended to keep competition away until at least 2028, though Novartis subsidiary Sandoz is looking to challenge this and submitted its own version of Enbrel to the FDA for review last month​.

The biosimilar is made at Biogen’s plant in Hillerød, Denmark, which uses the same people and development processes as its originator products, Altimari explained.

“We have a strong track record of manufacturing and supplying therapies to those who need them most.”

Related news

Show more

Related products

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Related suppliers

Follow us

Products

View more

Webinars